84 results
8-K
EX-99.1
OPGN
Opgen Inc
20 Sep 22
OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform
4:38pm
Exhibit 99.1
OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform
FIND, the global alliance … on feasibility study for the rapid detection of antimicrobial resistance (AMR) markers from blood culture
Feasibility phase of R&D project set
8-K
EX-99.1
OPGN
Opgen Inc
13 Jul 20
OpGen Subsidiary Curetis GmbH Secures Access to Additional EUR 5.0 Million Non-Dilutive Debt Financing Tranche from EIB
5:24pm
Tranche With 5-Year Interest Only Period Related to COVID-19 R&D Programs Across Multiple Platforms
- EIB Financing Tranche Available for Draw-Down … 2016, Curetis now stands to receive another EUR 5.0 million tranche of non-dilutive debt financing. This additional tranche is earmarked to co-fund R&D programs
8-K
EX-99.1
OPGN
Opgen Inc
20 Aug 20
Regulation FD Disclosure
4:34pm
phases of the R&D program on ARESdb in its R&D collaboration. Won new undisclosed global IVD company for feasibility and technology evaluation. Won … gross capacity reset for another $ 6.4 million EUR 5 million tranche in non - dilutive debt financing for COVID - 19 related R&D from the European
S-4/A
EX-10.35.2
OPGN
Opgen Inc
20 Dec 19
Registration of securities issued in business combination transactions (amended)
5:28pm
that Net Proceeds of Acquirer might include R&D funding which might be not easily separable. In such cases, Acquirer is — prior to the start of a project … only - entitled to request a waiver of such part of royalty payments that would reasonably result from to be received R&D funding. Such request shall
8-K
EX-99.1
OPGN
Opgen Inc
12 Aug 20
OpGen Reports Second Quarter 2020 Financial Results and Provides Business Update
4:24pm
not be more pleased with the quick and successful integration of our companies. Our team has worked around the clock to re-prioritize R&D efforts to not only … health institutions. Ares Genetics completed all three phases of the R&D program and successfully improved performance of molecular antibiotic
8-K
EX-99.1
t2dj033bg z4a2exjce
10 Nov 22
OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update
4:19pm
8-K
EX-99.2
17gqcxtc
4 Sep 19
Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses
6:55am
8-K
EX-99.1
apen q0lf
12 Aug 21
OpGen Reports Second Quarter 2021 Financial Results and Provides Business Update
5:05pm
8-K
EX-99.1
1sekpsnhy26uhb2km
12 Nov 21
OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update
6:35am
8-K
EX-99.1
8dtoneudz6n m61iz1
13 Jan 21
OpGen Announces Preliminary Unaudited Revenue for Fiscal 2020 and Provides Business Update
4:34pm
S-4/A
EX-10.36
ywvf5w g3cirvo
20 Dec 19
Registration of securities issued in business combination transactions (amended)
5:28pm
8-K
EX-99.1
3g0hpyfi 73imya0dm
15 May 23
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
5:11pm
8-K
EX-99.2
dv4i27d7h8oyx
14 Apr 20
OpGen Announces Preliminary Unaudited Revenue and Cash Position for First Quarter 2020 and Provides Business Update
5:22pm
8-K
EX-99.1
8de78da3g8e zr1
15 Oct 20
Results of Operations and Financial Condition
4:20pm
8-K
EX-99.1
twv8meh uk3xn5fpeh
30 Mar 23
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
5:11pm
8-K
EX-99.1
6hu3gzfzik87r2
15 Jul 20
Results of Operations and Financial Condition
5:17pm
8-K
EX-99.1
quh1gpuur920f
10 Aug 23
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
4:31pm
8-K
EX-99.1
5xd35e3 p0
29 Mar 22
OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
4:16pm
425
EX-99.1
ctsc3nb
24 Mar 20
Business combination disclosure
5:26pm
8-K
EX-99.2
00mefo
30 Mar 23
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
5:11pm